Autism Spectrum disorder (ASD) is characterized by social communication difficulties and repetitive behaviors/interests. It affects 1 in 88 children. Although there is emerging information on the biological differences leading to ASD, there are still no medicines approved for its core symptoms. This chair will focus on translating basic science findings into innovative therapies, by 1) improving clinical trials capacity in ASD in Canada, 2) selecting new molecular targets for therapies and testing new compounds, and 3) classifying genes, brain images and behaviour in ways that predict treatment response and thus personalize treatment for each child and youth with ASD.